Barclays Lowers Humana (HUM) Price Target amid Questions on Margin Expansion Outlook

Humana Inc. (NYSE:HUM) is included among the 14 Best GARP Stocks to Buy According to Analysts.

On February 25, Barclays lowered its price recommendation on Humana Inc. (NYSE:HUM) to $176 from $245. The firm reiterated an Equal Weight rating on the shares. It said it is “incrementally cautious” about the company’s expectation that Individual Medicare Advantage margins will double.

A February 14 Bloomberg report said Humana acquired Florida-based clinic operator MaxHealth. The company plans to integrate MaxHealth into its CenterWell Senior Primary Care division. This move expands Humana’s footprint in primary care for seniors. Financial terms were not disclosed. Reports suggested the deal was valued at around $1 billion.

MaxHealth operates more than 80 clinics across West and South Florida. It serves over 120,000 patients. The acquisition supports Humana’s broader effort to expand its primary care network. This comes at a time when its Medicare Advantage business faces pressure from rising care costs and tighter government reimbursement rates.

Humana Inc. (NYSE:HUM) provides insurance services and healthcare services through its CenterWell platform. The company operates through two main segments: Insurance and CenterWell.

While we acknowledge the potential of HUM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.